- 专利标题： COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF PROTEINURIA CHRONIC KIDNEY DISEASE
-
申请号： US18435463申请日： 2024-02-07
-
公开(公告)号： US20240307383A1公开(公告)日： 2024-09-19
- 发明人: Philip Ambery , Peter Greasley , Anne-Kristina Mercier , Mikael Sunnåker
- 申请人： AstraZeneca AB
- 申请人地址： SE Södertälje
- 专利权人： AstraZeneca AB
- 当前专利权人： AstraZeneca AB
- 当前专利权人地址： SE Södertälje
- 主分类号： A61K31/497
- IPC分类号： A61K31/497 ; A61K31/351 ; A61P9/12
摘要：
Methods for treating high proteinuria chronic kidney disease and/or at least one disease, disorder, or condition associated therewith in patients by the use of a fixed-dose combination of zibotentan and dapagliflozin are disclosed.
信息查询
IPC分类:
